Skip to main content

Tesla's Shocking Surge: Morgan Stanley's Bold Upgrade & the Future of FSD


Tesla ($TSLA) is riding high with a jaw-dropping upgrade from Morgan Stanley ($MS), catapulting the stock's value by over 22 points. 

MS shifted its stance from "Equal Weight" to "Overweight" and set a dazzling price target at $400, hinting at a potential 50% surge from its current standing. What's sparking this surge? It's all about Tesla's Dojo supercomputer, set to revolutionize Full Self-Driving (FSD). 

Elon Musk's excitement during the Q2 earnings call, claiming Dojo would make current metrics "look silly," is turning heads. But can Tesla deliver on its FSD promises? While Musk talks of full self-driving this year, skepticism abounds. 

The timeline for a Tesla robotaxi service remains uncertain. Amidst these shifts, Tesla is slashing vehicle prices to boost deliveries, prioritizing volume over margins. Musk's gamble is clear: more Teslas now mean more FSD revenue later. 

Watch the video for insights into this Tesla surge, breakout patterns, and key targets. 

Good Trading! 

Trading Risk Disclaimer 
All the information shared is provided for educational purposes only. Any trades placed upon the reliance of SharperTrades, LLC, are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward in trading stocks, cryptos, commodities, options, forex, and other trading securities, there is also a substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. SharperTrades, LLC, is not registered as an investment adviser with any federal or state regulatory agency. This is not an offer to buy or sell stocks, cryptos, forex, futures, options, commodity interests, or any other trading securities.

Popular posts from this blog

Nvidia’s AI Leadership Faces Challenges Amid Evolving Semiconductor Landscape

Super Micro Computer’s Volatile Comeback: A Long Road to Stability

Hims & Hers Health Surges Amid FDA Nomination, GLP-1 Opportunity